News archive

Researchers at Karolinska Institutet and the Public Health Agency of Sweden have studied newborn babies whose mothers tested positive for SARS-CoV-2 during pregnancy or childbirth. The results show that although babies born of test-positive mothers are more likely to be born early, extremely few were infected with COVID-19. The study, which is published in the esteemed journal JAMA, supports the Swedish recommendation not to separate mother and baby after delivery.

Malin Nygren-Bonnier, docent and head of the Division of Physiotherapy has been awarded a research grant from the Swedish Heart-Lung Foundation.

New weapon in the fight against Covid-19, while waiting for the vaccine. Listen to what Professor Qiang Pan-Hammarström at the Department of Biosciences and Nutrition, Karolinska Institutet, says in an interview in the newspaper Expressen.

Eight months after mild COVID-19, one in ten people still has at least one moderate to severe symptom that is perceived as having a negative impact on their work, social or home life. The most common long-term symptoms are a loss of smell and taste and fatigue. This is according to a study published in the journal JAMA, conducted by researchers at Danderyd Hospital and Karolinska Institutet in Sweden.

As the pandemic lingers on, more and more emphasis is being placed on the indirect, negative effects (i.e. collateral damage) of the pandemic and related restrictions. Sweden took a relatively lenient approach towards mitigating the pandemic during the spring of 2020, relying on voluntary adherence to recommendations and encouraging elderly to stay at home, avoid social gatherings and public transportation, and to remain physically active outdoors in a safe manner.

The European Commission has chosen COVID-X as project of the month. The project is supporting SMEs to advance their solutions in the fight against COVID-19.

An international consortium that includes researchers at Karolinska Institutet has developed a ‘double antibody’ that targets two different sites of the SARS-CoV-2 virus, thereby preventing the virus from mutating to resist the therapy. A study published in the scientific journal Nature shows that the antibody potently neutralises SARS-CoV-2 and its variants and protects against COVID-19 in mice.

Researchers at Karolinska Institutet are investigating the efficacy and safety of COVID-19 vaccines in a new study on patients with compromised immune systems, who can become seriously ill if they are affected by COVID-19. On February 23, the first patient in the study was vaccinated with an mRNA vaccine at Karolinska University Hospital. So far, the project has received two grants from the Knut and Alice Wallenberg Foundation of SEK 10 million in total.

How have social distancing and quarantine measures affected older individuals during the COVID-19 pandemic? Recent research lead by Professor Miia Kivipelto’s team provides some important insights – there were several negative effects but at the same time many lifestyles and behaviors did not substantially change during the first wave of the pandemic, and some even improved.

The European Commission has launched a contingency plan to meet the challenge of the various mutations of the coronavirus. KI and Karolinska University Hospital are contributing to a new network for the evaluation and testing of new vaccines.

Last year, researchers at Karolinska Institutet and the Max Planck Institute for Evolutionary Anthropology in Leipzig, Germany showed that a major genetic risk factor for severe COVID-19 is inherited from Neandertals. Now the same researchers show, in a study published in PNAS, that Neandertals also contributed a protective variant. Half of all people outside Africa carry a Neandertal gene variant that reduces the risk of needing intensive care for COVID-19 by 20 percent.

The success of the mRNA-based vaccines is a boost for the entire mRNA field and can lead to new treatments for completely different diseases. This is the view of Kenneth Chien, professor at Karolinska Institutet and co-founder of Moderna, one of the companies that has now developed a vaccine against COVID-19.

Treating severe COVID-19 patients with the anticancer drug bevacizumab may reduce mortality and speed up recovery, according to a small clinical study in Italy and China that was led by researchers at Karolinska Institutet in Sweden between February and April 2020. On average, blood oxygen levels, body temperature and inflammatory markers significantly improved in patients treated with a single dose of bevacizumab in addition to standard care. The research is published in Nature Communications.

It is necessary to develop additional COVID-19 vaccines, as different vaccine approaches have their advantages and disadvantages and may work synergistically. Researchers at Karolinska Institutet in Sweden now report that they have developed a prototype vaccine against SARS-CoV-2 using a DNA vaccine platform that is inexpensive, stable, easy to produce, and shows a good safety profile. A study published in Scientific Reports shows that the vaccine induces potent immune responses in mice.

Individual variations in how the immune system responds to SARS-CoV-2 appear to impact the severity of disease. Researchers at Karolinska Institutet have now been able to show that patients with severe COVID-19 have significantly elevated levels of a certain type of immune cells in their blood, called myeloid-derived suppressor cells. The study published in the Journal of Clinical Investigation may bring an increased understanding of how early immune responses impact disease severity.

Researchers at Karolinska Institutet have developed, in collaboration with researchers in Germany and the U.S., new small antibodies, also known as nanobodies, which prevent the SARS-CoV-2 coronavirus from entering human cells. The research study, published in Science, shows that a combined nanobody had a particularly good effect – even if the virus mutated. According to the researchers, the nanobodies have the potential to be developed into a treatment for COVID-19.

So far, little research has been done on the risk of children being seriously affected by COVID-19 when the schools were open. A study from Karolinska Institutet has now shown that one child in 130,000 was treated in an intensive care unit on account of COVID-19 during the period March-June. The work has been published as a letter to the editor in New England Journal of Medicine.

In some cases, immune cells in the lungs can contribute to worsening a virus attack. In a new study, researchers at Karolinska Institutet describe how different kinds of immune cells, called macrophages, develop in the lungs and which of them may be behind severe lung diseases. The study, which was published in Immunity, may contribute to future treatments for COVID-19, among other diseases.

Carin Lennartsson has been granted funding to collect data and research materials linked to the COVID-19 pandemic. The project is entitled “The Swedish Panel Study of Living Conditions of the Oldest Old – SWEOLD COVID-19”.

Rosaria Galanti receives NOK 10 million from NordForsk. The grant is awarded for collaborative projects between Nordic and Baltic Countries concerning clinical and public health aspects of COVID-19, especially in combination with the use of tobacco such as smoking and snus.

DOAC (direct oral anticoagulant) pills are used in the treatment of atrial fibrillation by preventing blood clots. Even though blood clots are thought to contribute to complications from the new coronavirus infection, users of this class of drug do not seem to be protected against severe COVID-19, reports a large Swedish registry study from Karolinska Institutet published in The Journal of Internal Medicine.

Concerns have been raised that the use of a common group of medications called RAS inhibitors could facilitate SARS-CoV-2 infection, impact COVID-19 disease severity and worsen prognosis. However, in a new nationwide registry-based study from Karolinska Institutet, including almost 1.4 million patients, use of RAS inhibitors was not associated with increased risk of hospitalisation or death from COVID-19. The study has been published in the European Journal of Heart Failure.

Worry about COVID-19 dominates some people’s lives in a way that has an impact on their health. A group of researchers at Karolinska Institutet in Sweden has developed a digital CBT programme that significantly reduced the participants’ unhelpful worry about the pandemic. The study is published in Psychotherapy and Psychosomatics and the programme is available through 1177 Vårdguiden.

Researchers at Karolinska Institutet in Sweden report promising results from an in vitro combination therapy against COVID-19. In a study published in EMBO Molecular Medicine, the researchers show that a combination of remdesivir, an approved drug against COVID-19, and hrsACE2, a medicine currently in phase II trials for COVID-19 treatment, reduced the viral load of SARS-CoV-2 and inhibited viral replication in cell cultures and organoids.

The rheumatoid arthritis drug baricitinib can block viral entry and reduce mortality in patients with moderate to severe COVID-19, according to translational research by an international team coordinated by researchers from Karolinska Institutet in Sweden. The findings, published in the journal Science Advances, support the continuation of ongoing randomized clinical trials.

By screening hundreds of synthetic antibodies, researchers at Karolinska Institutet in Sweden and EMBL Hamburg in Germany have identified an antibody that may prevent the new coronavirus from infecting human cells. The study, which is published in the journal Nature Communications, also shows how antibodies can be quickly produced in the event of future pandemics.

A study published in Nature shows that a segment of DNA that causes their carriers to have an up to three times higher risk of developing severe COVID-19 is inherited from Neandertals. The study was conducted by researchers at Karolinska Institutet and Max Planck Institute for Evolutionary Anthropology.

A type of anti-bacterial T cells, so-called MAIT cells, are strongly activated in people with moderate to severe COVID-19 disease, according to a study by researchers at Karolinska Institutet in Sweden that is published in the journal Science Immunology. The findings contribute to increased understanding about how our immune system responds against COVID-19 infection.

More than 10 percent of young and previously healthy people who develop severe COVID-19 have misguided antibodies that attack the immune system itself, and another 3.5 percent carry a specific genetic mutation. This is according to new research published in Science by an international consortium involving researchers at Karolinska Institutet in Sweden.

In a study published in JAMA researchers at Karolinska Institutet and Karolinska University Hospital have examined the association between a positive SARS-CoV-2 test during pregnancy and complications in mothers and their newborn babies. Almost two out of three pregnant women who tested positive for SARS-CoV-2 were asymptomatic and the researchers found no higher prevalence of complications during delivery or of ill-health in the neonates. However, preeclampsia was more common in infected women.

Researchers at Karolinska Institutet have developed a method for fast, cheap, yet accurate testing for COVID-19 infection. The method simplifies and frees the testing from expensive reaction steps, enabling upscaling of the diagnostics. This makes the method particularly attractive for places and situations with limited resources, for repeated testing and for moving resources from expensive diagnostics to other parts of the care chain. The study is published in Nature Communications.

Researchers at Karolinska Institutet are taking part in three projects funded as part of the EU’s second major investment in research on the new coronavirus sars-cov-2, COVID-19 and the pandemic. The total research grant for KI amounts to just over SEK 14 million.

When the coronavirus pandemic struck, a great many researchers put aside their current projects to devote themselves completely to the new virus. Meet three of those whose working life took an unexpected turn.

Researchers at Karolinska Institutet and Science for Life Laboratory in Sweden and Tor Vergata University of Rome in Italy have mapped the immune response in children affected by a rare but life-threatening inflammatory syndrome associated with COVID-19. The study, which is published in the scientific journal Cell, reveals that the inflammatory response differs from that in Kawasaki disease and severe acute COVID-19.

Researchers at Karolinska Institutet in Sweden have identified a small neutralizing antibody, a so-called nanobody, that has the capacity to block SARS-CoV-2 from entering human cells. The researchers believe this nanobody has the potential to be developed as an antiviral treatment against COVID-19. The results are published in the journal Nature Communications.

The Unit for Bioentrepreneurship (UBE) and the Health Informatics Centre (HIC) at the Department of Learning, Informatics, Management and Ethics, have been granted an EU Innovation Action Grant for the project COVID-X, which aims to contribute to the public health preparedness and response in the context of the ongoing pandemic of COVID-19 and to ensure the availability of critical technologies and tools.

A blood test on hospital admission showing the presence or absence of SARS-CoV-2 can identify patients at a high risk of severe COVID-19. Admitted patients without virus in their blood have a good chance of rapid recovery. This according to researchers at Karolinska Institutet and Danderyd Hospital in a new study published in the scientific journal Clinical Infectious Diseases.

Since 15 June, the requirements for distance learning have been eased and this autumn there will be a gradual return to KI's campus. But the unusual spring semester has yielded valuable lessons and experiences. Head of Division Ann Langius-Eklöf and lecturer Carina Georg recount what it was like for the nursing education programmes – to work against the clock.

On 17 March 2020, the Public Health Agency of Sweden encourages Swedish universities and upper-secondary schools to conduct distance learning in order to reduce the spread of COVID-19. The campus closes on 18 March, but teaching must continue. For KI’s teachers, it’s the start of an intensive undertaking, one that proved particularly challenging for the Unit for Teaching and Learning.

Researchers may have come one step closer toward understanding how the immune system contributes to severe COVID-19. In a study published in Science Immunology, researchers at Karolinska Institutet in Sweden show that so-called natural killer (NK) cells were strongly activated early after SARS-CoV-2 infection but that the type of activation differed in patients with moderate and severe COVID-19. The discovery contributes to our understanding of development of hyperinflammation in some patients.

New research from Karolinska Institutet shows that the degree of frailty, a measure of a person’s functional level before contracting the disease, can better predict COVID-19 survival than the patient’s age. The analysis of 250 multimorbid older adults who received care for COVID-19 at the Aging Theme at Karolinska University Hospital in Huddinge, Sweden also shows that three out of four of these patients survived. The study has been published in the scientific journal JAMDA.

COVID-19 hits nations worldwide. Social restrictions are being put in place in an effort to limit the spread of the corona virus and save lives.

A new study from Karolinska Institutet and Karolinska University Hospital shows that many people with mild or asymptomatic COVID-19 demonstrate so-called T-cell-mediated immunity to the new coronavirus, even if they have not tested positively for antibodies. According to the researchers, this means that public immunity is probably higher than antibody tests suggest. The article has been published in the esteemed scientific journal Cell. [This news article has been updated]

The pharmaceutical company Chiesi donates SEK 320,000 to a research project at Karolinska Institutet to develop a new method for large scale COVID-19 tests. The goal is to be able to follow the development of the virus in populations and community groups. The project is led by Nicola Crosetto, researcher at the Department of Medical Biochemistry and Biophysics.

By conducting advanced analyses of immune system activation in patients with severe COVID-19, researchers at Karolinska Institutet have managed to identify several cell types that play a key part in the immune response to the new coronavirus and the hyperinflammation seen in severe cases of the disease. The results are published in the scientific journal Cell Reports Medicine.

The drug tocilizumab, which is used in the treatment of various forms of arthritis, is associated with shorter time on ventilation and shorter hospital stays for patients with severe COVID-19, a new study from Karolinska Institutet and Karolinska University Hospital published in The Journal of Internal Medicine reports.

A literature review coordinated by Karolinska Institutet in Sweden and McMaster University in Canada demonstrates that cloth face masks provide clinically useful levels of filtration, which has the potential to reduce the spread of viruses such as SARS-CoV-2. The findings, now published in the journal Mayo Clinic Proceedings, support the wearing of cloth masks to reduce the spread of the new coronavirus, according to the researchers.

Injuries in the nervous system of patients with severe COVID-19 are revealed by magnetic resonance imaging and computed tomography. In a study of 185 patients, researchers at KI and Karolinska University Hospital show an affection of microscopic blood vessels and inflammation in the brain, meninges and nerves. The results are published in Radiology.

The COVID-19 pandemic caused by the new coronavirus has created an unprecedented public health challenge globally. Little was known about how the infecting cells respond to the virus and how the virus hijacks the host cellular machinery. A study led by researchers at Karolinska Institutet published in Emerging Microbes & Infection gives new insights into the virus-host interplay enabling newer ideas to tackle the virus.

Researchers at Karolinska Institutet in Sweden have developed a new method for analysing intact tumour samples in 3D on a molecular level. The study is a collaboration with Karolinska University Hospital and is published in Nature Biomedical Engineering. Now the researchers are planning to use the method to study tissue samples from COVID-19 patients in the hope that it will provide information on where and how the new coronavirus attacks different organs.